Cboe UK EUR

Faes Farma, S.A. (FAEE.XC)

4.1300
0.0000
(0.00%)
At close: April 23 at 1:00:02 PM GMT+1
Loading Chart for FAEE.XC
  • Previous Close 4.1300
  • Open 4.1125
  • Bid --
  • Ask --
  • Day's Range 4.1300 - 4.1300
  • 52 Week Range 3.1950 - 4.1300
  • Volume 2,804
  • Avg. Volume 126
  • Market Cap (intraday) 1.341B
  • Beta (5Y Monthly) 0.29
  • PE Ratio (TTM) 11.47
  • EPS (TTM) 0.3600
  • Earnings Date Jul 28, 2025 - Aug 1, 2025
  • Forward Dividend & Yield 0.16 (3.80%)
  • Ex-Dividend Date Jan 9, 2025
  • 1y Target Est --

Faes Farma, S.A., researches, develops, produces, and markets pharmaceutical products, healthcare products, and raw materials worldwide. It operates through Pharmaceutical and Healthcare Specialties; Animal Nutrition and Health; and Pharmaceutical Raw Materials segments. It offers products for various therapeutic areas. The company also provides animal nutrition and health products. Faes Farma, S.A. was incorporated in 1933 and is headquartered in Leioa, Spain.

faesfarma.com

1,775

Full Time Employees

December 31

Fiscal Year Ends

Recent News: FAEE.XC

View More

Performance Overview: FAEE.XC

Trailing total returns as of 5/22/2025, which may include dividends or other distributions. Benchmark is IBEX 35... (^IBEX) .

YTD Return

FAEE.XC
30.94%
IBEX 35... (^IBEX)
23.71%

1-Year Return

FAEE.XC
35.88%
IBEX 35... (^IBEX)
25.98%

3-Year Return

FAEE.XC
17.53%
IBEX 35... (^IBEX)
68.22%

5-Year Return

FAEE.XC
41.00%
IBEX 35... (^IBEX)
113.10%

Compare To: FAEE.XC

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: FAEE.XC

View More

Valuation Measures

Annual
As of 5/21/2025
  • Market Cap

    1.32B

  • Enterprise Value

    1.28B

  • Trailing P/E

    11.60

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.61

  • Price/Book (mrq)

    1.77

  • Enterprise Value/Revenue

    2.58

  • Enterprise Value/EBITDA

    9.94

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    20.85%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    524.02M

  • Net Income Avi to Common (ttm)

    109.27M

  • Diluted EPS (ttm)

    0.3600

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    72.14M

  • Total Debt/Equity (mrq)

    3.62%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: FAEE.XC

View More

Company Insights: FAEE.XC

Research Reports: FAEE.XC

View More
Waiting for permission
Allow microphone access to enable voice search

Try again.